Head to Head Survey: Windtree Therapeutics (WINT) vs. Trillium Therapeutics (TRIL)

Windtree Therapeutics (OTCMKTS: WINT) and Trillium Therapeutics (NASDAQ:TRIL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk.

Analyst Ratings

This is a summary of current recommendations and price targets for Windtree Therapeutics and Trillium Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Windtree Therapeutics 0 1 0 0 2.00
Trillium Therapeutics 0 0 3 0 3.00

Trillium Therapeutics has a consensus target price of $14.00, suggesting a potential upside of 87.92%. Given Trillium Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Trillium Therapeutics is more favorable than Windtree Therapeutics.

Insider & Institutional Ownership

0.3% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 47.2% of Trillium Therapeutics shares are owned by institutional investors. 0.8% of Windtree Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.


This table compares Windtree Therapeutics and Trillium Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Windtree Therapeutics -1,205.47% N/A -345.52%
Trillium Therapeutics N/A -248.39% -65.21%

Volatility & Risk

Windtree Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, Trillium Therapeutics has a beta of 13.72, indicating that its stock price is 1,272% more volatile than the S&P 500.

Valuation & Earnings

This table compares Windtree Therapeutics and Trillium Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Windtree Therapeutics $2.04 million 119.29 -$39.49 million ($71.83) -0.05
Trillium Therapeutics N/A N/A -$23.96 million ($2.57) -2.90

Trillium Therapeutics has lower revenue, but higher earnings than Windtree Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.


Trillium Therapeutics beats Windtree Therapeutics on 9 of the 13 factors compared between the two stocks.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

What are top analysts saying about Windtree Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Windtree Therapeutics and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit